Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Brokerages

Pfizer Inc. (NYSE:PFE) has been assigned an average rating of “Hold” from the twenty-three research firms that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $28.1905.

A number of equities research analysts have weighed in on PFE shares. Guggenheim boosted their target price on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Royal Bank Of Canada initiated coverage on shares of Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target on the stock. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. HSBC raised their target price on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Finally, Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court orders Poland and Romania to accept €1.9B ($2.2B) of Pfizer COVID-19 vaccine deliveries — a material recognized/near‑term revenue win that supports sales visibility. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: England offered Pfizer’s RSV vaccine to an additional ~3 million older adults — a rollout expansion that could lift recurring vaccine revenue in key markets. Pfizer RSV vaccine offered to 3M more older adults in England
• Positive Sentiment: Technicals and sentiment remain constructive in parts of the market — commentary notes PFE trading above its 50- and 200-day SMAs and outpacing peers at times, which can support short‑term buying interest. PFE Stock Trades Above 200 & 50-Day SMA for 3 Months
• Neutral Sentiment: Pfizer is closing its South San Francisco research site to cut costs and concentrate R&D investments — could boost near‑term margins but raises questions about long‑term pipeline capacity. Pfizer Site Closure Puts Cost Focus And R&D Productivity In Spotlight
• Neutral Sentiment: Corporate reshaping: Pfizer exits part of the ViiV HIV venture as partners adjust ownership — reduces direct HIV exposure but simplifies portfolio. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Investor pieces on valuation and options (covered-call strategies) highlight yield attraction but offer no company‑level catalyst — useful for income investors but neutral for PFE’s share direction. Boost Pfizer’s Already Hefty 6% Dividend Yield With A Covered Call
• Negative Sentiment: U.S. policy risk: the Trump administration proposed tariffs up to 100% on branded drugs — unless makers agree to U.S. pricing deals or on‑shore manufacturing commitments — creating large downside regulatory risk for branded drug revenue and margins. Trump Administration Unveils Up to 100% Tariff on Branded Drugs
• Negative Sentiment: Clinical/program execution concerns: Pfizer and BioNTech paused recruitment for a U.S. trial of an updated COVID vaccine due to low enrollment — signals demand softness for new COVID boosters and complicates future vaccine growth. Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Analyst/watchdog skepticism: commentary argues Pfizer’s large dividend may mask slower organic growth, keeping some investors cautious about forward earnings momentum. Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem

Pfizer Stock Down 0.6%

Shares of NYSE:PFE opened at $28.37 on Friday. Pfizer has a 52-week low of $20.92 and a 52-week high of $28.75. The company has a market capitalization of $161.29 billion, a PE ratio of 20.86 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company has a fifty day moving average of $27.03 and a 200-day moving average of $25.79.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 earnings per share. On average, equities analysts predict that Pfizer will post 2.95 EPS for the current fiscal year.

Institutional Trading of Pfizer

Several institutional investors have recently added to or reduced their stakes in PFE. Horizon Financial Services LLC raised its holdings in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer during the fourth quarter worth $28,000. HFM Investment Advisors LLC increased its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the period. Finally, Grey Fox Wealth Advisors LLC bought a new position in Pfizer during the third quarter worth $29,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.